Need Help?

Specific BRCA and immune configurations determine optimal response to platinum-based chemotherapy in triple negative breast and ovarian carcinomas (COH_TNBC_RNAseq)

To determine the trascriptional profiles of Triple Negative Breast Cancers (COH cohort)

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001008542 Illumina HiSeq 4000 41
Publications Citations
Genomic and epigenomic <i>BRCA</i> alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.
Sci Transl Med 14: 2022 eabn1926
13